Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
Open accessPublished version of a preprint
Abstract
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor receptor (Her-1 or ErbB1) and Her-2. It is conceivable that lapatinib may inhibit the function of ATP-binding cassette (ABC) transporters by binding to their ATP-binding sites. The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters. Our results showed that lapatinib significantly enhanced the sensitivity to ABCB1 or ABCG2 substrates in cells expressing these transporters, although a small synergetic effect was observed in combining lapatinib and conventional chemotherapeutic agents in parental sensitive MCF-7 or S1 cells. Lapatinib alone, however, did not significantly alter the sensitivity of non-ABCB1 or non-ABCG2 substrates in sensitive and resistant cells. Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E217βG by ABCG2. Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [125I]iodoarylazidoprazosin in a concentration-dependent manner. However, lapatinib did not affect the expression of these transporters at mRNA or protein levels. Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBv200 cell xenografts in nude mice. Overall, we conclude that lapatinib reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function. These findings may be useful for cancer combinational therapy with lapatinib in the clinic. [Cancer Res 2008;68(19):7905–14]
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Lapatinib is an FDA approved drug for treatment of several HER2 driven cancers and has been shown to also directly inhibit drug efflux activity of MDR1, both in cancer cells and in in vivo tumor models.
“The ErbB receptor inhibitor lapatinib is an U.S. Food and Drug Administration (FDA) approved drug for the treatment of several HER2 driven cancers and has been shown to also directly inhibit the drug efflux activity of MDR1, both in cancer cells and in in vivo tumor models (36).”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [36]
Lapatinib is a competitive inhibitor of MDR1 both in vitro and in vivo.
“lapatinib has previously been shown to be a competitive inhibitor of MDR1 both in vitro and in vivo (36)”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,426 · see citing works
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., Luca, A. D., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., Feo, G. D., Caponigro, F., & Salomon, D. S. (2005) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,035 · see citing works
The Human ATP-Binding Cassette (ABC) Transporter SuperfamilyPreprint
Dean, M. C., Rzhetsky, A., & Allikmets, R. L. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,758 · see citing works
P-glycoprotein: from genomics to mechanism
Ambudkar, S. V., Kimchi‐Sarfaty, C., Sauna, Z. E., & Gottesman, M. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206948 · Cited by 1,076 · see citing works
Self-citationMultidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Doyle, L. A., & Ross, D. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206938 · Cited by 1,056 · see citing works
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K., O’Neil, B. H., Marcom, P. K., Ellis, M. J., Overmoyer, B. A., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619 · see citing works
The MRP family of drug efflux pumps
Kruh, G. D., & Belinsky, M. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206953 · Cited by 615 · see citing works
The Role of ABC Transporters in Drug Resistance, Metabolism and Toxicity
Glavinas, H., Krajcsi, P., Cserepes, J., & Sarkadi, B. (2004) · Current Drug Delivery · doi:10.2174/1567201043480036 · Cited by 559 · see citing works
Litman, T., Brangi, M., Hudson, E., Fetsch, P. A., Abati, A. D., Ross, D. D., Miyake, K., Resau, J. H., & Bates, S. E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.2011 · Cited by 538 · see citing works
Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis
Donnenberg, V. S., & Donnenberg, A. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005276905 · Cited by 457 · see citing works
Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Pérez, W. Y., Robey, R. W., van de Laar, A., Litman, T., Dean, M. C., & Bates, S. E. (2001) · PubMed · Cited by 429 · see citing works
Self-citationMutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity
Robey, R. W., Honjo, Y., Morisaki, K., Nadjem, T., Runge, S., Risbood, M., Poruchynsky, M. S., & Bates, S. E. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601370 · Cited by 367 · see citing works
Self-citationLapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
(2007) · New England Journal of Medicine · doi:10.1056/nejmx070016 · Cited by 350 · see citing works
Chemotherapy-induced resistance by ATP-binding cassette transporter genes
Gillet, J. A., Efferth, T., & Remacle, J. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.05.002 · Cited by 336 · see citing works
Shi, Z., Peng, X.-X., Kim, I., Shukla, S., Si, Q.-S., Robey, R. W., Bates, S. E., Shen, T., Ashby, C. R., Fu, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2686 · Cited by 315 · see citing works
Self-citationChen, Z., Robey, R. W., Belinsky, M. G., Shchaveleva, I., Ren, X. Q., Sugimoto, Y., Ross, D. D., Bates, S. E., & Kruh, G. D. (2003) · PubMed · Cited by 305 · see citing works
Self-citationNahta, R., Yuan, L. X. H., Du, Y., & Esteva, F. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0423 · Cited by 267 · see citing works
Agulnik, M., Cohen, E. E. W., Cohen, R. B., Chen, E. X., Vokes, E. E., Hotte, S. J., Winquist, E., Laurie, S. A., Hayes, D. N., Dancey, J. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8612 · Cited by 262 · see citing works
Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells.
Cornwell, M. M., Gottesman, M. M., & Pastan, I. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)57491-9 · Cited by 255 · see citing works
Chu, I. M., Blackwell, K., Chen, S., & Slingerland, J. M. (2005) · Cancer Research · doi:10.1158/0008-5472.18.65.1 · Cited by 250 · see citing works
Polli, J. W., Humphreys, J. E., Harmon, K. A., Castellino, S., O'Mara, M., Olson, K. L., John‐Williams, L. S., Koch, K. M., & Serabjit‐Singh, C. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018374 · Cited by 245 · see citing works
Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib
Cusatis, G., Gregorc, V., Li, J., Spreafico, A., Ingersoll, R., Verweij, J., Ludovini, V., Villa, E., Hidalgo, M. M., Sparreboom, A., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj469 · Cited by 242 · see citing works
Venne, A., Li, S., Mandeville, R., Kabanov, A. V., & Alakhov, V. Y. (1996) · PubMed · Cited by 225 · see citing works
Erlichman, C., Boerner, S. A., Hallgren, C. G., Spieker, R. S., Wang, X., James, C. D., Scheffer, G. L., Maliepaard, M., Ross, D. D., Bible, K. C., et al. (2001) · PubMed · Cited by 224 · see citing works
Elkind, N. B., Szentpétery, Z., Apáti, Á., Özvegy‐Laczka, C., Várady, G., Ujhelly, O., Szabó, K., Homolya, L., Váradi, A., Buday, L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3303 · Cited by 223 · see citing works
Sauna, Z. E., & Ambudkar, S. V. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.6.2515 · Cited by 218 · see citing works
Self-citationGrant, S. (2002) · Frontiers in bioscience · doi:10.2741/grant · Cited by 203 · see citing works
[37] Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells
Ambudkar, S. V. (1998) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(98)92039-0 · Cited by 199 · see citing works
Self-citationLi, J., Cusatis, G., Brahmer, J. R., Sparreboom, A., Robey, R. W., Bates, S. E., Hidalgo, M. M., & Baker, S. D. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.3.3763 · Cited by 191 · see citing works
Self-citationShen, G., Xu, C., Hu, R., Jain, M. R., Gopalkrishnan, A., Nair, S., Huang, M., Chan, J. Y., & Kong, A. T. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0293 · Cited by 179 · see citing works
Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
Johnston, S. R. D., & Leary, A. F. (2006) · Drugs of today · doi:10.1358/dot.2006.42.7.985637 · Cited by 174 · see citing works
Fu, L., Zhang, Y.-X., Liang, Y. F., Yang, X., & Pan, Q. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00356-2 · Cited by 154 · see citing works
Self-citationCharacterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance
Fu, L., Liang, Y.-J., Deng, L., Ding, Y. P., Chen, L., Ye, Y.-L., Yang, X., & Pan, Q. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0742-5 · Cited by 145 · see citing works
Self-citationLapatinib in the treatment of breast cancer
Higa, G. M., & Abraham, J. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.9.1183 · Cited by 145 · see citing works
Shi, Z., Liang, Y.-J., Chen, Z., Wang, X., Wang, X., Ding, Y. P., Chen, L., Yang, X.-P., & Fu, L. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.1.2236 · Cited by 141 · see citing works
Self-citationMitomo, H., Kato, R., Ito, A., Kasamatsu, S., Ikegami, Y., Kii, I., Kudō, A., Kobatake, E., SUMINO, Y., & Ishikawa, T. (2003) · Biochemical Journal · doi:10.1042/bj20030150 · Cited by 123 · see citing works
Bence, A. K., Anderson, E. B., Halepota, M. A., Doukas, M. A., DeSimone, P. A., Davis, G. A., Smith, D. A., Koch, K. M., Stead, A. G., Mangum, S., et al. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000047104.45929.ea · Cited by 120 · see citing works
Kerr, K. M., Sauna, Z. E., & Ambudkar, S. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010044200 · Cited by 106 · see citing works
Self-citationShukla, S., Robey, R. W., Bates, S. E., & Ambudkar, S. V. (2006) · Biochemistry · doi:10.1021/bi060552f · Cited by 103 · see citing works
Self-citationYang, C.-H., Huang, C.-J., Yang, C.-S., Chu, Y.-C., Cheng, A., Whang‐Peng, J., & Yang, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0641 · Cited by 95 · see citing works
(2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-11-cor3 · Cited by 91 · see citing works
Özvegy‐Laczka, C., Köblös, G., Sarkadi, B., & Váradi, A. (2004) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2004.11.005 · Cited by 80 · see citing works
Dai, C.-L., Xiong, H.-Y., Tang, L.-F., Zhang, X., Liang, Y.-J., Zeng, M., Chen, L., Wang, X., & Fu, L. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0420-0 · Cited by 63 · see citing works
Self-citationABCG2 Harboring the Gly482 Mutation Confers High-Level Resistance to Various Hydrophilic Antifolates
Shafran, A., Ifergan, I., Bram, E. E., Jansen, G., Kathmann, I., Peters, G. J., Robey, R. W., Bates, S. E., & Assaraf, Y. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4547 · Cited by 61 · see citing works
Self-citationReversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318
Chen, L., Liang, Y.-J., Ruan, J., Ding, Y. P., Wang, X., Shi, Z., Gu, L., Yang, X.-P., & Fu, L. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357043879 · Cited by 61 · see citing works
Self-citationJohnston, S. R. D., Martin, L., Leary, A. F., Head, J. E., & Dowsett, M. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.05.019 · Cited by 60 · see citing works
Midgley, R. S., Kerr, R. S., Flaherty, K. T., Stevenson, J. P., Pratap, S., Koch, K. M., Smith, D. A., Versola, M., Fleming, R. A., Ward, C., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm366 · Cited by 56 · see citing works
Flow cytometry: A new approach for the molecular profiling of breast cancer
Lostumbo, A., Mehta, D. G., Setty, S., & Nunez, R. (2005) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.09.007 · Cited by 52 · see citing works
Screening Novel, Potent Multidrug-Resistant Modulators From Imidazole Derivatives
Chen, L., Wu, X.-P., Ruan, J., Liang, Y.-J., Ding, Y. P., Shi, Z., Wang, X., Gu, L., & Fu, L. (2004) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/0965040041292378 · Cited by 50 · see citing works
Self-citationOverexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein
Shi, Z., Liang, Y.-J., Chen, Z., Wang, X., Ding, Y., Chen, L., & Fu, L. (2007) · Oncology Reports · doi:10.3892/or.17.4.969 · Cited by 49 · see citing works
Self-citationColey, H. M., Shotton, C. F., Ajose-Adeogun, A. O., Modjtahedi, H., & Thomas, H. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.07.022 · Cited by 49 · see citing works
Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer
Mukherjee, A., Dhadda, A., Shehata, M., & Chan, S. Y. T. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.13.2189 · Cited by 40 · see citing works
Johnston, S. R. D. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00992 · Cited by 37 · see citing works
Dent, P. (2002) · Frontiers in bioscience · doi:10.2741/a782 · Cited by 31 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866 · see citing works
Self-citationKathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 783 · see citing works
Self-citationRole of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 676 · see citing works
Clinical pharmacokinetics of tyrosine kinase inhibitors
van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503 · see citing works
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
Natarajan, K., Xie, Y., Baer, M. R., & Ross, D. D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.002 · Cited by 408 · see citing works
Mi, Y.-J., Liang, Y.-J., Huang, H.-B., Zhao, H.-Y., Wu, C.-P., Wang, F., Tao, L.-Y., Zhang, C.-Z., Dai, C.-L., Tiwari, A. K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0111 · Cited by 337 · see citing works
Self-citationImprovement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I. K., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 320 · see citing works
Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Agarwal, S., Hartz, A. M. S., Elmquist, W. F., & Bauer, B. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797440186 · Cited by 275 · see citing works
Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer
Tang, Y., Wang, Y., Kiani, M. F., & Wang, B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.05.012 · Cited by 266 · see citing works
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Dong, J., Qin, Z., Zhang, W., Cheng, G., Assaraf, Y. G., Ashby, C. R., Chen, Z., Cheng, X., & Qin, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 259 · see citing works
Self-citationThe Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy
Wu, C., Hsieh, C., & Wu, Y. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200261n · Cited by 235 · see citing works
Self-citationBeretta, G. L., Cassinelli, G., Pennati, M., Zuco, V., & Gatti, L. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.062 · Cited by 234 · see citing works
Renal Drug Transporters and Drug Interactions
Ivanyuk, A., Livio, F., Biollaz, J., & Buclin, T. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0506-8 · Cited by 221 · see citing works
Human ABCG2: structure, function, and its role in multidrug resistance.
Mo, W., & Zhang, J. (2012) · PubMed Central · Cited by 218 · see citing works
Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Tiwari, A. K., Sodani, K. S., Dai, C., Ashby, C. R., & Chen, Z. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795164048 · Cited by 211 · see citing works
Self-citationTiwari, A. K., Sodani, K. S., Wang, S., Kuang, Y., Ashby, C. R., Chen, X. '., & Chen, Z. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.002 · Cited by 210 · see citing works
Self-citationWu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 202 · see citing works
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Jonas, O., Landry, H. M., Fuller, J. E., Santini, J. T., Baselga, J., Tepper, R. I., Cima, M. J., & Langer, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010564 · Cited by 189 · see citing works
The role of ABC transporters in ovarian cancer progression and chemoresistance
Ween, M. P., Armstrong, M., Oehler, M. K., & Ricciardelli, C. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.012 · Cited by 182 · see citing works
Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance
Shi, Z., Tiwari, A. K., Shukla, S., Robey, R. W., Singh, S., Kim, I., Bates, S. E., Peng, X., Abraham, I., Ambudkar, S. V., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3820 · Cited by 172 · see citing works
Self-citationDiscovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Wu, C., Ohnuma, S., & Ambudkar, S. V. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795163887 · Cited by 172 · see citing works
Self-citationNoguchi, K., Katayama, K., & Sugimoto, Y. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s38295 · Cited by 168 · see citing works
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Shukla, S., Chen, Z., & Ambudkar, S. V. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.005 · Cited by 169 · see citing works
Self-citationRole of ABC transporters in cancer chemotherapy
Sun, Y.-L., Patel, A. S., Kumar, P., & Chen, Z. (2012) · 癌症：英文版 · doi:10.5732/cjc.011.10466 · Cited by 169 · see citing works
Self-citationHu, S., Chen, Z., Franke, R. M., Orwick, S. J., Zhao, M., Rudek, M. A., Sparreboom, A., & Baker, S. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0048 · Cited by 162 · see citing works
Self-citationATP-binding cassette efflux transporters and MDR in cancer
Pote, M. S., & Gacche, R. N. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103537 · Cited by 162 · see citing works
Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway
Jiang, L., Wang, P., Sun, Y.-J., & Wu, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1251-7 · Cited by 146 · see citing works
Wu, S., & Fu, L. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0775-3 · Cited by 144 · see citing works
Self-citationEndogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
Spiegel, S., Milstien, S., & Grant, S. (2011) · Oncogene · doi:10.1038/onc.2011.267 · Cited by 141 · see citing works
Han, B., Jin, B., Chu, T., Niu, Y., Dong, Y., Xu, J., Gu, A., Zhong, H., Wang, H., Zhang, X., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30806 · Cited by 141 · see citing works
Self-citationThe drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136 · see citing works
Tiwari, A. K., Sodani, K. S., Dai, C.-L., Abuznait, A. H., Singh, S., Xiao, Z., Patel, A. S., Talele, T. T., Fu, L., Kaddoumi, A., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.001 · Cited by 128 · see citing works
Self-citationTyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
Anreddy, N., Gupta, P., Kathawala, R. J., Patel, A. S., Wurpel, J. N. D., & Chen, Z. (2014) · Molecules · doi:10.3390/molecules190913848 · Cited by 125 · see citing works
Self-citationVergara, D., Bellomo, C., Zhang, X., Vergaro, V., Tinelli, A., Lorusso, V., Rinaldi, R., LVOV, Y. M., Leporatti, S., & Maffia, M. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.10.014 · Cited by 121 · see citing works
Dai, C.-L., Liang, Y.-J., Wang, Y.-S., Tiwari, A. K., Yan, Y., Wang, F., Chen, Z., Tong, X.-Z., & Fu, L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.027 · Cited by 120 · see citing works
Self-citationInvestigational ABC transporter inhibitors
Falasca, M., & Linton, K. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679339 · Cited by 120 · see citing works
Moving towards dose individualization of tyrosine kinase inhibitors
Klümpen, H., Samer, C. F., Mathijssen, R. H. J., Schellens, J. H. M., & Gurney, H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.08.006 · Cited by 120 · see citing works
Brózik, A., Hegedüs, C., Erdei, Z., Hegedűs, T., Özvegy‐Laczka, C., Szakács, G., & Sarkadi, B. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.562892 · Cited by 119 · see citing works
Tong, X.-Z., Wang, F., Liang, S.-L., Zhang, X., He, J., Chen, X.-G., Liang, Y.-J., Mi, Y., To, K. K. W., & Fu, L. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.007 · Cited by 118 · see citing works
Self-citationDrug interactions with solid tumour-targeted therapies
Thomas‐Schoemann, A., Blanchet, B., Bardin, C., Noé, G., Boudou, P., Vidal, M., & Goldwasser, F. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.007 · Cited by 112 · see citing works
Metabolism considerations for kinase inhibitors in cancer treatment
Duckett, D. R., & Cameron, M. D. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.506873 · Cited by 111 · see citing works
Collins, D. M., Conlon, N. T., Kannan, S., Verma, C. S., Eli, L. D., Lalani, A. S., & Crown, J. P. (2019) · Cancers · doi:10.3390/cancers11060737 · Cited by 108 · see citing works
Targeting CD133 antigen in cancer
Ferrandina, G., Petrillo, M., Bonanno, G., & Scambia, G. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903005616 · Cited by 107 · see citing works
Ji, N., Yang, Y., Cai, C., Lei, Z., Wang, J., Gupta, P., Shukla, S., Ambudkar, S. V., Kong, D., & Chen, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.007 · Cited by 105 · see citing works
Self-citationAdamska, A., & Falasca, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i29.3222 · Cited by 104 · see citing works
Zhang, J.-Y., Tao, L.-Y., Liang, Y.-J., Chen, L.-M., Mi, Y.-J., Zheng, L.-S., Wang, F., She, Z.-G., Lin, Y.-C., To, K. K. W., et al. (2010) · Marine Drugs · doi:10.3390/md8041469 · Cited by 103 · see citing works
Self-citationZhou, W., Zhang, X., Cheng, C., Wang, F., Wang, X., Liang, Y.-J., To, K. K. W., Wang, Z., Huang, H., & Fu, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01849.x · Cited by 101 · see citing works
Self-citationQayoom, H., Wani, N. A., Alshehri, B., & Mir, M. A. (2021) · Future Oncology · doi:10.2217/fon-2021-0172 · Cited by 100 · see citing works
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance
Kuang, Y., Shen, T., Chen, X. '., Sodani, K. S., Hopper-Borge, E. A., Tiwari, A. K., Lee, J. W. K. K., Fu, L., & Chen, Z. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.08.021 · Cited by 99 · see citing works
Self-citationXia, C. Q., & Smith, P. G. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079129 · Cited by 96 · see citing works
Zhao, X.-Q., Xie, J., Chen, X.-G., Sim, H. M., Zhang, X., Liang, Y.-J., Singh, S., Talele, T. T., Sun, Y.-L., Ambudkar, S. V., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076299 · Cited by 92 · see citing works
Self-citationAgarwal, S., Mittapalli, R. K., Zellmer, D. M., Gallardo, J. L., Donelson, R., Seiler, C., Decker, S. A., SantaCruz, K. S., Pokorny, J. L., Sarkaria, J. N., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0552 · Cited by 92 · see citing works
Chen, T., Wang, C., Liu, Q., Meng, Q., Sun, H., Huo, X., Sun, P., Peng, J., Liu, Z., Yang, X., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.987062 · Cited by 92 · see citing works
Zheng, L.-S., Wang, F., Li, Y., Zhang, X., Chen, L., Liang, Y.-J., Dai, C.-L., Yan, Y., Tao, L.-Y., Mi, Y., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005172 · Cited by 91 · see citing works
Self-citationBauer, J. A., Ye, F., Marshall, C. B., Lehmann, B. D., Pendleton, C. S., Shyr, Y., Arteaga, C. L., & Pietenpol, J. A. (2010) · Breast Cancer Research · doi:10.1186/bcr2595 · Cited by 90 · see citing works
Mechanisms of acquired resistance to tyrosine kinase inhibitors
Chen, Y., & Fu, L. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.10.007 · Cited by 89 · see citing works
Self-citationZattoni, I. F., Delabio, L. C., Dutra, J. D. P., Kita, D. H., Scheiffer, G., Hembecker, M., Pereira, G. D. S., Moure, V. R., & Valdameri, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114346 · Cited by 88 · see citing works
zu Schwabedissen, H. E. M., & Kroemer, H. K. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-14541-4_9 · Cited by 89 · see citing works
Zhang, R., Qiao, H., Chen, S., Chen, X., Dou, K., Li, W., & Zhang, J. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1210728 · Cited by 86 · see citing works
Correction: Reversal of Multidrug Resistance by Lapatinib
(2008) · Cancer Research · doi:10.1158/0008-5472.can-68-24-cor · Cited by 86 · see citing works
Pick, A., & Wiese, M. (2012) · ChemMedChem · doi:10.1002/cmdc.201100543 · Cited by 83 · see citing works
Ding, P.-R., Tiwari, A. K., Ohnuma, S., Lee, J. W. K. K., An, X., Dai, C.-L., Lu, Q.-S., Singh, S., Yang, D., Talele, T. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019329 · Cited by 81 · see citing works
Self-citationDoxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer
Wang, H., Li, F., Du, C., Wang, H., Mahato, R. I., & Huang, Y. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400687w · Cited by 81 · see citing works
Self-citationAi, Y., Zhu, B., Ren, C., Kang, F., Li, J., Huang, Z., Lai, Y., Peng, S., Ding, K., Tian, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01203 · Cited by 79 · see citing works
Markers of Tumor-Initiating Cells Predict Chemoresistance in Breast Cancer
Gong, C., Yao, H., Liu, Q., Chen, J., Shi, J., Su, F., & Song, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015630 · Cited by 80 · see citing works
Wu, C., Lusvarghi, S., Wang, J.-C., Hsiao, S.-H., Huang, Y.-H., Hung, T., & Ambudkar, S. V. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00274 · Cited by 79 · see citing works
Self-citationStefan, S. M., & Wiese, M. (2018) · Medicinal Research Reviews · doi:10.1002/med.21510 · Cited by 77 · see citing works
Wu, C., Sim, H., Huang, Y.-H., Liu, Y., Hsiao, S.-H., Cheng, H.-W., Li, Y., Ambudkar, S. V., & Hsu, S. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.003 · Cited by 76 · see citing works
Self-citationSerie, D., Crook, J. E., Necela, B. M., Dockter, T., Wang, X. L., Asmann, Y. W., Fairweather, D., Bruno, K. A., Colón‐Otero, G., Perez, E. A., et al. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000302 · Cited by 76 · see citing works
The Challenge of Exploiting ABCG2 in the Clinic
Robey, R. W., Ieranò, C., Zhan, Z., & Bates, S. E. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795163913 · Cited by 73 · see citing works
Self-citationTyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas
Carcaboso, A. M., Elmeliegy, M. A., Shen, J., Juel, S. J., Zhang, Z. M., Calabrese, C. R., Tracey, L., Waters, C. M., & Stewart, C. F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4264 · Cited by 72 · see citing works
Shen, T., Kuang, Y., Ashby, C. R., Yu, L., Angel, C., Zhou, Y. Q., Chen, X., Tiwari, A. K., Hopper-Borge, E. A., Ouyang, J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007520 · Cited by 71 · see citing works
Self-citationLi, X., Dong, Y., Wang, W., Wang, H., Chen, Y., Shi, G., Yi, J., & Wang, J. (2012) · Stem Cells and Development · doi:10.1089/scd.2011.0709 · Cited by 71 · see citing works
Hu, H., Lin, Z., He, B., Dai, W., Wang, X., Wang, J., Zhang, X., Zhang, H., & Zhang, Q. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.018 · Cited by 70 · see citing works
ABCG2/BCRP: Specific and Nonspecific Modulators
Peña‐Solórzano, D., Stark, S., König, B., Sierra, C. A., & Ochoa‐Puentes, C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21428 · Cited by 70 · see citing works
Kelishady, P. D., Saadat, E., Ravar, F., Javar, H. A., & Dorkoosh, F. A. (2014) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2014.965323 · Cited by 69 · see citing works
Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter
Qiu, J.-G., Zhang, Y., Li, Y., Zhao, J., Zhang, W., Jiang, Q., Mei, X.-L., Xue, Y., Qin, W.-M., Yang, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3820 · Cited by 68 · see citing works
Xu, W., Zheng, X., Pang, X., Zhang, Z., & Zhang, Q. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.10.018 · Cited by 67 · see citing works
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478
Shi, Z., Tiwari, A. K., Shukla, S., Robey, R. W., Kim, I.-W., Parmar, S., Bates, S. E., Si, Q.-S., Goldblatt, C. S., Abraham, I., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.007 · Cited by 66 · see citing works
Self-citationJi, N., Yang, Y., Cai, C., Lei, Z., Wang, J., Gupta, P., Teng, Q., Chen, Z., Kong, D., & Yang, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01236 · Cited by 66 · see citing works
Self-citationDual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment
Stanković, T., Dinić, J., Podolski-Renić, A., Musso, L., Burić, S. S., Dallavalle, S., & Pešić, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180607094856 · Cited by 65 · see citing works
Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
Bighetti‐Trevisan, R. L., Sousa, L. O., CASTILHO, R. M., & Almeida, L. O. (2019) · Stem Cells International · doi:10.1155/2019/9618065 · Cited by 62 · see citing works
Wang, Y., Zhang, Y., Kathawala, R. J., & Chen, Z. (2014) · Cancers · doi:10.3390/cancers6041925 · Cited by 62 · see citing works
Self-citationSodani, K. S., Tiwari, A. K., Singh, S., Patel, A. S., Xiao, Z., Chen, J.-J., Sun, Y.-L., Talele, T. T., & Chen, Z. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.02.028 · Cited by 61 · see citing works
Self-citationThe pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy
Wu, C., & Ambudkar, S. V. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.12.001 · Cited by 61 · see citing works
Self-citationChun, S., Kwon, Y., Nam, K., & Kim, S. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.03.009 · Cited by 61 · see citing works
Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin.
Yuan, Z., Shi, X., Qiu, Y., Jia, T., Yuan, X., Zou, Y., Liu, C., Yu, H., Yuan, Y., He, X., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5410 · Cited by 61 · see citing works
Krchniakova, M., Skoda, J., Neradil, J., Chlapek, P., & Veselska, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093157 · Cited by 61 · see citing works
Aird, K. M., Allensworth, J. L., Batinic̈‐Haberle, I., Lyerly, H. K., Dewhirst, M. W., & Devi, G. R. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1568-1 · Cited by 60 · see citing works
Zhou, X., Chen, R., Yu, Z., Li, R., Li, J., Zhao, X., Song, S., Liu, J., & Huang, G. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0331-3 · Cited by 59 · see citing works
Wang, X.-K., To, K. K. W., Huang, L.-Y., Xu, J.-H., Yang, K., Wang, F., Huang, Z.-C., Ye, S., & Fu, L. (2014) · Oncotarget · doi:10.18632/oncotarget.2647 · Cited by 59 · see citing works
Self-citationVera, A. A. D., Gupta, P., Lei, Z., Liao, D., Narayanan, S., Teng, Q., Reznik, S. E., & Chen, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.020 · Cited by 59 · see citing works
Self-citationABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors
Deng, J., Shao, J., Markowitz, J. S., & An, G. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1389-0 · Cited by 58 · see citing works
Mimeault, M., Johansson, S. L., Hénichart, J., Depreux, P., & Batra, S. K. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1013 · Cited by 58 · see citing works
The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
Hsu, W.-T., Huang, C., Yen, C. Y. T., Cheng, A., & Hsieh, P. C. H. (2018) · Theranostics · doi:10.7150/thno.23207 · Cited by 58 · see citing works
Wang, Y., Kathawala, R. J., Zhang, Y., Patel, A. S., Kumar, P., Shukla, S., Fung, K. L., Ambudkar, S. V., Talele, T. T., & Chen, Z. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.006 · Cited by 56 · see citing works
Self-citationABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer
Hasanabady, M. H., & Kalalinia, F. (2016) · Journal of Biosciences · doi:10.1007/s12038-016-9601-5 · Cited by 57 · see citing works
Kathawala, R. J., Wang, Y., Ashby, C. R., & Chen, Z. (2013) · 癌症：英文版 · doi:10.5732/cjc.013.10122 · Cited by 56 · see citing works
Self-citationTao, L.-Y., Liang, Y.-J., Wang, F., Chen, L., Yan, Y., Dai, C.-L., & Fu, L. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0949-1 · Cited by 55 · see citing works
Self-citationBreslin, S., Lowry, M. C., & O’Driscoll, L. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.445 · Cited by 53 · see citing works
- Authors
- Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., Chen, L.-M., Shi, C.-J., Ambudkar, S. V., Chen, Z.-S., & Fu, L.-W.
- Affiliations
- Sun Yat-sen University (CN)
- St. John's University (US)
- National Institutes of Health (US)
- 1State Key Laboratory for Oncology in South China, Cancer Center, Sun Yat-Sen University, Guangzhou, China;
- ORCID
- Venue
- Cancer Research
- Published
- 2008-09-30
- Volume
- 68
- Issue
- 19
- Pages
- 7905-7914
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC2652245
- OpenAlex
- W2098064809
- Cited by
- 386
- References
- 54
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 22 · 2021: 17 · 2020: 32 · 2019: 26 · 2018: 20 · 2017: 23 · 2016: 22 · 2015: 26 · 2014: 43 · 2013: 16 · 2012: 38
- FWCI
- 11.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- St. John's University (579-1110)
- Sun Yat-sen University
- National Institutes of Health
- National Cancer Institute (Z01BC010030, Z01BC010622)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- lapatinib, multidrug resistance reversal, P-glycoprotein, ABCG2, ABC transporters, drug efflux, doxorubicin accumulation, methotrexate transport, paclitaxel, tyrosine kinase inhibitors, combination chemotherapy
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Lapatinib, Adenosine Triphosphatases, Animals, Antineoplastic Combined Chemotherapy Protocols, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Mice, Nude, Neoplasm Proteins, Neoplasms, Quinazolines, Transfection, Up-Regulation, Gene Expression Regulation, Neoplastic, Paclitaxel, Drug Resistance, Multiple, ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, Xenograft Model Antitumor Assays, Tumor Burden, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
